Gapping up
In reaction to strong earnings/guidance:
- N/A.
M&A news:
- CCC +62.1% (to be acquired by Kuraray for $21.50 per share)
- CRH +1.9% (acquires Ash Grove Cement for $3.5 bln)
Other news:
- ITUS +11.4% (renews research agreement for continued development of Cchek and enters into an exclusive option agreement to license intellectual property covering a proprietary CAR-T technology w/ The Wistar Institute)
- BCRX +9.9% (announces FDA approval of a sNDA for RAPIVAB)
- AMPH +6.8% (received FDA approval of its ANDA for sodium bicarbonate injection 8.4% in 50 mL Luer-Jet Prefilled Syringe System)
- ABUS +6.6% (continued strength)
- PRQR +5.5% (presents data 'in a relevant disease model, establishing proof of concept for its novel and proprietary Axiomer RNA editing platform technology)
- TPRE +4.5% (to join S&P SmallCap 600)
- APC +4.3% (Anadarko Petroleum announces $2.5 bln share-repurchase program; co also reaffirms the guidance it had previously provided for the deepwater Gulf of Mexico, DJ and Delaware basin assets )
- FOLD +4.2% (confirms being granted orphan drug designation by the FDA for ATB200/AT2221)
- GVP +3.6% (GSE Systems, Inc. acquires Absolute Consulting, Inc., a provider of technical consulting and staffing solutions to the global nuclear power industry, for $8.75 mln in cash )
- APRN +3.3% higher after Albertsons announced the acquisition of Plated, a premier meal kit service)
- KND +2.7% (sees $20 mln pre-tax hit to Q3 earnings due to Hurricanes Harvey and Irma)
- AERI +2.6% (confirms FDA Advisory Committe meeting scheduled for October 13 to review its NDA for Rhopressa for the treatment of patients with open-angle glaucoma or ocular hypertension)
- AMD +1.5% (extending late move higher on reports that Tesla is wokring with AMD for an AI self-sdriving chip)
- MDXG +1.3% (responds to 'deceptive short seller articles' )
Analyst comments:
- RDY +6.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- GBT +3.5% (initiated with a Buy at Needham)
- DB +1.2% (upgraded to Hold from Reduce at HSBC Securities)
